Literature DB >> 26763537

Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia.

Scott M Grundy1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26763537     DOI： 10.1038/nrcardio.2015.208

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  5 in total

1.  Proof That Lower Is Better--LDL Cholesterol and IMPROVE-IT.

Authors:  John A Jarcho; John F Keaney
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

2.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

3.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

Authors:  Jordan Fulcher; Rachel O'Connell; Merryn Voysey; Jonathan Emberson; Lisa Blackwell; Borislava Mihaylova; John Simes; Rory Collins; Adrienne Kirby; Helen Colhoun; Eugene Braunwald; John La Rosa; T R Pedersen; Andrew Tonkin; Barry Davis; Peter Sleight; Maria Grazia Franzosi; Colin Baigent; Anthony Keech
Journal:  Lancet       Date:  2015-01-09       Impact factor: 79.321

4.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Authors:  Marc S Sabatine; Robert P Giugliano; Stephen D Wiviott; Frederick J Raal; Dirk J Blom; Jennifer Robinson; Christie M Ballantyne; Ransi Somaratne; Jason Legg; Scott M Wasserman; Robert Scott; Michael J Koren; Evan A Stein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

5.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Authors:  Jennifer G Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S Stroes; Gisle Langslet; Frederick J Raal; Mahfouz El Shahawy; Michael J Koren; Norman E Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J P Kastelein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245
  5 in total
  4 in total

Review 1.  Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.

Authors:  Olivier S Descamps; Uwe Fraass; Ricardo Dent; Winfried März; Ioanna Gouni-Berthold
Journal:  Int J Clin Pract       Date:  2017-07-27       Impact factor: 2.503

2.  Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance.

Authors:  Rene C Adam; Ivory J Mintah; Corey A Alexa-Braun; Lisa M Shihanian; Joseph S Lee; Poulabi Banerjee; Sara C Hamon; Hye In Kim; Jonathan C Cohen; Helen H Hobbs; Cristopher Van Hout; Jesper Gromada; Andrew J Murphy; George D Yancopoulos; Mark W Sleeman; Viktoria Gusarova
Journal:  J Lipid Res       Date:  2020-07-09       Impact factor: 5.922

Review 3.  Natural Products to Counteract the Epidemic of Cardiovascular and Metabolic Disorders.

Authors:  Birgit Waltenberger; Andrei Mocan; Karel Šmejkal; Elke H Heiss; Atanas G Atanasov
Journal:  Molecules       Date:  2016-06-22       Impact factor: 4.411

4.  Haplotypes on pig chromosome 3 distinguish metabolically healthy from unhealthy obese individuals.

Authors:  Simona D Frederiksen; Peter Karlskov-Mortensen; Sameer D Pant; Maryse Guerin; Philippe Lesnik; Claus B Jørgensen; Susanna Cirera; Camilla S Bruun; Thomas Mark; Merete Fredholm
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.